Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (20)

Showing 1-10 of 20

Sorted By:

A-Z
Z-A

Previous Next

BG-68501-101: A PHASE 1A/1B STUDY OF BG-68501, A SELECTIVE CDK2 INHIBITOR, IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Safety, tolerability, (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors.
BGB-B455-101: A Phase 1, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B455 in Patients With Selected Advanced or Metastatic Solid Tumors
Ph 1 Open-Label Study Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Prelim Antitumor Activity of BGB-B455 in Pts w/Selected Adv/Met Solid Tumors
CPG-01-201: Early Phase Clinical Trial to Evaluate COM701 in PSOC
Goal of trial is to learn if experimental antibody COM701 delays progression of ovarian cancer in Relapsed PSOC. It will also learn about the safety of COM701.
D6900C00003 GOG-3110 ENGOT-EN28 (BLUESTAR-Endometrial01): A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy
Ph 3 Study of (AZD8205) Monotherapy vs MD’s Choice in Pts w/ B7-H4-Selected Adv/Met Endometrial CA Progressed On/After Platinum-Based Chemo & Anti-PD-1/Anti-PD-L1 Therapy
D781DC00001_GOG-3098_DESTINY-Endometrial01: An Open-Label, Randomized, Controlled, Multicenter, Phase III Study of First-Line Trastuzumab Deruxtecan (T-DXd) Monotherapy versus SoC in Patients with HER2-Expressing (IHC3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
Ph 3 Study of First-Line Trastuzumab Deruxtecan Monotherapy vs SoC in Pts w/HER2-Expressing (IHC3+/IHC 2+), Mismatch Repair Proficient, Primary Adv/Rec Endometrial Cancer
DS8201-772: A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112)
Trial to evaluate efficacy and safety of T-DXd with bevacizumab vs bevacizumab alone as first-line maintenance therapy in HER2-expressing ovarian cancer
Faeth_FTH-PIK-201: An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel, and a Substudy Evaluating PIKTOR with Paclitaxel plus an Insulin-Suppressing Diet, in Patients with Advanced or Recurrent Endometrial Cancer
Ph 2 Trial Evaluating Sapanisertib&Serabelisib (PIKTOR) w/Paclitaxel & Substudy Eval. PIKTOR w/Paclitaxel + Insulin-Suppressing Diet, in Pts w/ Adv/Rec Endometrial Cancer
GCT1184-02: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer
Compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemo drugs that are already approved and used for platinum-resistant ovarian cancer.
GOG 3083_XPORT-EC-042: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Ph 3, Rand,Placebo-Controlled,Double-Blind,Multicenter Trial ofSelinexor in Maint.Therapy After Systemic Therapy for Ptsw/p53 Wild-Type, Adv or Recurrent Endometrial Carcinoma
GOG 3083_XPORT-EC-042: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Phase 3, Ran Placebo-Controlled,Double-Blind, Multicenter Trial of Selinexor in Maint. Therapy After Systemic Therapy for Pt's W/ p53 Wild-Type, Adv./Rec Endometrial Carcinoma

Previous Next